Skip to main content
Premium Trial:

Request an Annual Quote

NCI's caBIG Seeks Third-Party Service Providers

NEW YORK (GenomeWeb News) — The National Cancer Institute’s Cancer Biomedical Informatics Grid program has issued a request for information “to gauge third-party interest in becoming a caBIG service provider,” according to a statement this week from Booz Allen Hamilton, caBIG’s primary contractor.
 
According to the RFI, the caBIG initiative is moving toward “self-sustainability,” which means that participants “will require support services to realize successful application of caBIG tools and products.”
 
Under the proposed service provider program, third-party organizations will provide user application support, informatics architecture and development support, code development services, and other services.
 
Service providers would be compensated directly by the organization that is benefiting from the support services, according to the RFI.
 
The RFI can be downloaded here. Responses are due Oct. 26.

Filed under

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.